Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
NF-κB2 (p100) limits TNF-α–induced osteoclastogenesis
Sakae Tanaka, Hiroyasu Nakano
Sakae Tanaka, Hiroyasu Nakano
Published September 21, 2009
Citation Information: J Clin Invest. 2009;119(10):2879-2881. https://doi.org/10.1172/JCI40629.
View: Text | PDF
Commentary

NF-κB2 (p100) limits TNF-α–induced osteoclastogenesis

  • Text
  • PDF
Abstract

Bone undergoes a continuous cycle of renewal, and osteoclasts — the cells responsible for bone resorption — play a pivotal role in bone homeostasis. This resorption is largely mediated by inflammatory cytokines such as TNF-α. In this issue of the JCI, Yao et al. demonstrate that the NF-κB precursor protein NF-κB2 (p100) acts as a negative regulator of osteoclastogenesis (see the related article beginning on page 3024). TNF-α induced a sustained accumulation of p100 in osteoclast precursors, and TNF-α–induced osteoclast formation was markedly increased in Nfkb2–/– mice. They also found that TNF receptor–associated factor 3 (TRAF3) is involved in the posttranslational regulation of p100 expression. These results suggest that blockade of the processing of p100 is a novel strategy to treat TNF-α–related bone diseases such as RA.

Authors

Sakae Tanaka, Hiroyasu Nakano

×

Figure 1

Schematic representation of RANKL and TNF-α–induced signaling in osteoclast precursors.

Options: View larger image (or click on image) Download as PowerPoint
Schematic representation of RANKL and TNF-α–induced signaling in osteocl...
New elements of these signaling pathways, as elucidated by Yao et al. (13) in their study in this issue of the JCI, are grouped within the purple box. In unstimulated cells, NIK is constitutively degraded by the TRAF3/TRAF2/c-IAP1/2 complex (red dashed arrows). RANKL activates NIK and induces both the canonical and noncanonical NF-κB pathways, which play critical roles in osteoclastogenesis (blue arrows). On the other hand, TNF-α solely activates the canonical pathways (green arrows) and induces the upregulation of TRAF3 by suppressing TRAF3 degradation (brown dashed arrow and line). TRAF3 in turn binds to and further accelerates the degradation of NIK. A decrease in NIK leads to the accumulation of NF-κB2 (p100) by suppressing its processing to p52 (blue arrows). In addition, TNF-α induces expression of Nfkb2 in a RelA-dependent fashion. These signaling pathways lead to the accumulation of p100, thereby inhibiting osteoclast differentiation. The mechanism by which TNF-α stabilizes TRAF3 is currently unknown. The proteasome-dependent degradation pathways are indicated by dashed lines.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts